Publications &

Presentations

In our pursuit of scientific advancement we are committed to sharing our acquired knowledge through actively publishing our data in peer-reviewed journals and academic conferences. We aim to provide a deeper understanding through extensive study and analysis on ileal bile acid transporter (IBAT) inhibition, for both the scientific and patient communities.

Research Updates

Featured Presentations & Publications
Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH-PFIC): a randomized placebo-controlled phase 3 study
Thompson, et al. Oral Presentation, AASLD 2022.
VIEW PRESENTATION
Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: Interim results from the RISE study
Gonzales, et al. Poster Presentation, AASLD 2022.
VIEW PRESENTATION
Real-world safety experience in patients with Alagille syndrome treated with maralixibat
Himes, et al. Poster Presentation, AASLD 2022.
VIEW PRESENTATION
Maralixibat-treated patients with Alagille syndrome demonstrate improved event-free survival in a natural history comparison with patients from the GALA database: application of real-world evidence analytics
Kamath, et al. Poster Presentation, NASPGHAN 2022.
VIEW POSTER
Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life
Kamath BM, et al. The Journal of Pediatrics. 2022; ISSN 0022-3476.
VIEW PUBLICATION

Latest Research Updates

Filter by topic
  • SELECT
  • Show all
  • Alagille syndrome
  • Biliary atresia
  • Health economics and outcomes research
  • IBAT inhibition
  • Intrahepatic cholestasis of pregnancy
  • LIVMARLI (maralixibat)
  • Patient-reported outcomes validation
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis
  • Progressive familial intrahepatic cholestasis
  • Volixibat
Until a relevant regulatory agency has approved a Mirum product for a specific disease or population, any scientific presentations regarding such disease or population are not to be considered instruction on the appropriate use of Mirum products or clinical candidates.